Intranasal Fluticasone Propionate Is Effective and Well-Tolerated in Adolescents with Seasonal Allergic Rhinitis

This two-week, double-blind, randomized, parallel-group, placebo-controlled study examined the efficacy and tolerability of intranasal fluticasone propionate (200 mcg once daily or 100 meg twice daily) in 12- to 17-year-old adolescents (n = 243) with seasonal allergic rhinitis. Both clinician- and patient-rated symptom scores for nasal obstruction, sneezing, nasal itching, and rhinorrhea were significantly lower in the groups treated with intranasal fluticasone propionate compared with the placebo-treated group. Clinician ratings of overall response to therapy also were significantly more favorable for each intranasal fluticasone propionate dosing regimen compared with placebo. There were no statistically significant differences between the intranasal fluticasone propionate groups in nasal symptom scores or clinician-rated overall response to therapy. No severe or unusual adverse events were reported in any of the groups. Morning plasma cortisol concentrations after 2 weeks of therapy did not differ among...